5
Jan
2018
Spark Sets $850K Bar, Microsoft’s Bet on AI for Immune Mapping, & Startup Financings Galore
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account. 
Share:
4
Jan
2018
Microsoft Makes Nine-Figure Bet on Adaptive’s TCR-Antigen Map; BioNTech Hauls in $270M for 10-Drug Cancer Pipeline
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
3
Jan
2018
Scholar Rock, After a Year on Pause, Snags $47M to Take New Tack Against SMA
Spinal muscular atrophy is one of the ongoing success stories in biotech. But that doesn’t mean the story’s over. Cambridge, Mass.-based Biogen won a first-of-its-kind FDA approval a year ago with a new antisense oligonucleotide, licensed from Ionis Pharmaceuticals. The drug, nusinersen (Spinraza), allows kids with a crippling disease to produce greater amounts of the SMN protein they need to...Read More
Share:
3
Jan
2018
Finding a Path in Biotech VC: The Long Run Podcast With Bob More
Today’s guest on The Long Run is Bob More. He’s a managing director with Alta Partners, a healthcare-focused venture capital firm. More got started as a young pup in biotech in the 1980s. He moved around between big companies and small companies. He advanced to a couple well-known healthcare VC firms – Domain Associates and Frazier Healthcare Partners. Before joining...Read More
Share:
21
Dec
2017
How Did BioMarin Make It? The Long Run Podcast With Daniel Levine & Dan Maher
Today on The Long Run, we’re talking about the history of BioMarin Pharmaceutical, one of biotech’s most successful rare disease drug developers. The guests on the show are Daniel Levine and Dan Maher. They are the co-authors of “A Rare Breed: How people and perseverance built BioMarin into one of the world’s most innovative companies.” These two made for a...Read More
Share:
20
Dec
2017
Five Things That I Think I Know About (My) Happiness
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
18
Dec
2017
Walk & Talk With Me on Powell Street at #JPM18
JPM is right around the corner. You are probably packing your calendar with one-on-one meetings, programmed events, and evening receptions. So am I. But this year, I’m adding a fun new wrinkle. I’d like you to join me. Let’s start with the basics: I need to train for the Everest Climb to Fight Cancer at Fred Hutch. San Francisco has...Read More
Share:
14
Dec
2017
A16Z Rakes in New $450M Fund to Build ‘Engineering Biology’ Plays
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
13
Dec
2017
Accelerator, Backed by Corporate VCs, Spreads Wings – But Not in Boston & SF
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
11
Dec
2017
Biotech’s Test: Root for a Tax Windfall Or Support the Next Generation of Scientists?
Grad students are underpaid and underappreciated. Many barely scrape by. Stagnant grant funding for science and uncertain career prospects are the norm. Yet we all know grad students are the mitochrondria of the scientific enterprise. Without them, PIs wouldn’t be looking like geniuses in Nature and Science. Biotech companies wouldn’t have enough of the worker bees they need. Now we...Read More
Share:
8
Dec
2017
Sage Crushes Depression Trial, Spark’s Hemophilia Tour de Force, & CVS-Aetna Megadeal
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
6
Dec
2017
Obsidian Therapeutics Gets $49.5M to Bring CAR-T Dosing Under Control
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
6
Dec
2017
The Long Run Podcast: Steve Graham on Racism in Corporate America
Steve Graham is today’s guest on The Long Run podcast. Chances are you don’t know his name, but Graham is a major behind-the-scenes player in biotech. Graham is the co-chair of the life sciences practice at the law firm Fenwick & West, and managing partner of the firm’s Seattle office. He has been working with biotech boards, handling corporate law,...Read More
Share:
6
Dec
2017
“You Went to SITC and All You Got Was This TR Post? (Part 2)
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
4
Dec
2017
The Microbiome: New Technology, Commercial Challenges, and Opportunities
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
1
Dec
2017
Foundation Medicine Wins FDA/CMS Two-Fer, Azar Calls Out High Drug Prices & Biogen Buys MS Challenger
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
29
Nov
2017
The Long Run Podcast: Steve Holtzman on Becoming a Biotech Political Activist
Steve Holtzman is the latest guest on The Long Run podcast. He’s the president and CEO of Boston-based Decibel Therapeutics, a venture-backed startup developing treatments for hearing loss. Holtzman has been a familiar figure around biotech for more than 30 years. He has had leadership roles at Millennium Pharmaceuticals, Infinity Pharmaceuticals, and Biogen. Little known fact: He was a founder...Read More
Share:
29
Nov
2017
Codiak, Aspiring to Make Exosome Drugs for Cancer, Nabs $76M to March Into Clinic
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
27
Nov
2017
Female Contraception, Health and Liberty
[Note: This article was first published on the Leadership and Biotechnology Blog.] Against the backdrop of tax reform, ongoing dialogue around sexual harassment, deepening investigations into the role of Russia in our elections, the crisis in Korea, attempts to dismantle the Affordable Care Act, and continued attempts to restrict immigration and remove Dreamers from the USA, President Trump’s assault on...Read More
Share:
21
Nov
2017
You Went to SITC And All You Got Was This TR Post? (Part 1)
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
